Continue to Site

Drug Discovery and Development

NanoString debuts spatial molecular imaging platform

By |

NanoStringNanoString Technologies Inc. (NSDQ:NSTG) has announced a spatial molecular imaging platform for multiplexed analysis of RNA and protein expression for individual cells within intact tissue samples. 

The spatial molecular imaging (SMI) platform supports tissue samples of Formalin-fixed paraffin-embedded and fresh-frozen specimens as well as organoids. 

The SMI platform is designed to complement the company’s GeoMx digital spatial profiler, which supports the analysis of hundreds to thousands of RNAs or proteins from single cells within morphologically intact tissue samples. The profiler supports cellular and sub-cellular resolution. 

“Spatial imagers measuring RNA and protein in situ at single-cell and sub-cell resolution are expected to emerge as an important product category over the next several years,” said Brad Gray, NanoString president and CEO, in prepared remarks. 

The SMI will be formally available in the first half of 2021. 

NanoString’s GeoMx has been a moneymaker for the company, helping to accelerate revenue growth in 2020. According to a briefing note from the investment bank UBS, the 3D spatial tool addresses one of the most attractive end-market opportunities in diagnostic tools.

Filed Under: Drug Discovery and Development
Tagged With: , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development